Galmed Announces Allowance Of New Patent For Aramchol For The Treatment Of Pulmonary And Dermal Fibrosis
Portfolio Pulse from Benzinga Newsdesk
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced the allowance of a Japanese patent related to treatment of pulmonary and dermal fibrosis. The patent strengthens and extends the protection of its lead compound, Aramchol, until November 2037. A similar patent was already granted in Mexico, while approval in the US and the rest of the world is pending. Aramchol has shown significant anti-fibrotic effects in a pre-clinical model of lung fibrosis.
September 26, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Galmed Pharmaceuticals has secured a Japanese patent for Aramchol, a treatment for pulmonary and dermal fibrosis. This strengthens the protection of Aramchol until November 2037. Approval in the US and globally is pending.
The allowance of the Japanese patent for Aramchol strengthens Galmed's intellectual property rights, potentially deterring competition and securing future revenue streams. The pending approval in the US and globally could further enhance the company's market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100